Upregulation of p53 expression in patients with colorectal cancer by administration of curcumin

Cancer Investigation

Volumn 29, Issue 3, 2011, Pages 208-213

  He, Zhen Yu ^a   Shi, Chuan Bing ^a   Wen, Hao ^a   Li, Fang Long ^a   Wang, Bao Lin ^a   Wang, Jie ^b  

^a THE SECOND AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Cancer; Colon; Curcumin

Indexed keywords

CURCUMIN; DNA; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER TISSUE; COLORECTAL CANCER; DNA FRAGMENTATION; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; FEMALE; GENERAL CONDITION IMPROVEMENT; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREGULATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; UPREGULATION; WEIGHT GAIN;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BODY WEIGHT; CACHEXIA; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; CURCUMIN; DIGESTIVE SYSTEM SURGICAL PROCEDURES; DOUBLE-BLIND METHOD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; MALE; NEOPLASM STAGING; RADIOTHERAPY; TUMOR NECROSIS FACTOR-ALPHA; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 79951601296     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2010.550592     Document Type: Article

References (20)

1. Gruen RL, Pitt V, Green S, Parkhill A, Campbell D, Jolley D. The effect of provider case volume on cancer mortality: systematic review and meta-analysis. CA Cancer J Clin 2009;59(3):192-211.
2. Köhne CH, Lenz HJ. Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer. Oncologist 2009;14(5):478-488.
3. Calviello G, Serini S, Piccioni E, Pessina G. Antineoplastic effects of N-3 polyunsaturated fatty acids in combination with drugs and radiotherapy: preventive and therapeutic strategies. Nutr Cancer 2009;61(3):287-301.
4. Sinkovics JG, Horvath JC. Natural and genetically engineered viral agents for oncolysis and gene therapy of human cancers. Arch ImmunolTher Exp (Warsz) 2008;56(Suppl 1):3s-59s.
5. Goel A, Jhurani S, Aggarwal BB. Multi-targeted therapy by curcumin: how spicy is it? Mol Nutr Food Res 2008;52(9):1010-1030.
6. Chiu TL, Su CC. Curcumin inhibits proliferation and migration by increasing the Bax to Bcl-2 ratio and decreasing NF-kappaBp65 expression in breast cancer MDA-MB-231 cells. Int J Mol Med 2009;23(4):469-475.
7. Harikumar KB, Kuttan G, Kuttan R. Inhibition of progression of erythroleukemia induced by Friend virus in BALB/cmice by natural products-berberine, curcumin and picroliv. J ExpTherOncol 2008;7(4):275-284.
8. William BM, Goodrich A, Peng C, Li S. Curcumin inhibits proliferation and induces apoptosis of leukemic cells expressing wildtype or T315I-BCR-ABL and prolongs survival of mice with acute lymphoblastic leukemia. Hematology 2008;13(6):333-343.
9. Yang PC, Xing Z, Berin CM, Soderholm JD, Feng BS, Wu L, Yeh C. TIM-4 expressed by mucosal dendritic cells plays a critical role in food antigen-specificTh2 differentiation and intestinal allergy. Gastroenterology 2007;133(5):1522-1533. (Pubitemid 350029737)
10. Tu YH, Oluwole C, Struiksma S, Perdue MH, Yang PC. Mast cells modulate transport of CD23/IgE/antigen complex across human intestinal epithelial barrier. North Am JMed Sci 2009;1(1):16-24.
11. Dewys WD, Begg C, Lavin PT, Band PR, Bennett JM, Bertino JR, Cohen MH, Douglass HO, Jr. Engstrom PF, Ezdinli EZ, Horton J, Johnson GJ, Moertel CG, Oken MM, Perlia C, Rosenbaum C, Silverstein MN, Skeel RT, Sponzo RW, Tormey DC. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med 1980;69(4):491-497. (Pubitemid 10018703)
12. Tisdale MJ. Cachexia in cancer patients. Nat Rev Cancer 2002;2:862-871. (Pubitemid 37328904)
13. Walsh D, Mahmoud F, Barna B. Assessment of nutritional status and prognosis in advanced cancer: interleukin-6, C-reactive protein, and the prognostic and inflammatory nutritional index. Support Care Cancer 2003;11:60-62. (Pubitemid 36722854)
14. Lieffers JR, Mourtzakis M, Hall KD, McCargar LJ, Prado CM, Baracos VE. A viscerally driven cachexia syndrome in patients with advanced colorectal cancer: contributions of organ and tumor mass to whole-body energy demands. Am J Clin Nutr 2009;89(4):1173-1179.
15. Johnson G, Sallé A, Lorimier G, Laccourreye L, Enon B, Blin V, Jousset Y, Arnaud JP, Malthièry Y, Simard G, Ritz P. Cancer cachexia:measured and predicted resting energy expenditures for nutritional needs evaluation. Nutrition 2008;24(5):443-450.
16. Lelbach A, Muzes G, Feher J. Current perspectives of catabolic mediators of cancer cachexia. Medical Science Monitor 2007;13: RA168-RA173. (Pubitemid 47416708)
17. Zhang Y, Wang S, Li Y, Xiao Z, Hu Z, Zhang J. Sophocarpine and matrine inhibit the production of TNF-alpha and IL-6 in murine macrophages and prevent cachexia-related symptoms induced by colon26 adenocarcinoma in mice. Int Immunopharmacol 2008;8(13-14): 1767-1772.
18. Villegas I, Sánchez-Fidalgo S, Alarcón, de la Lastra C. Newmechanisms and therapeutic potential of curcumin for colorectal cancer. Mol Nutr Food Res 2008;52(9):1040-1061.
19. Teodoro JG, Parker AE, Zhu X, Green MR. p53-mediated inhibition of angiogenesis through up-regulation of a collagen prolyl hydroxylase. Science 2006;313:968-971. (Pubitemid 44267388)
20. Phillips DC, Garrison SP, Jeffers JR, Zambetti GP. Assays to measure p53-dependent and-independent apoptosis. Methods Mol Biol 2009;559:143-159.